ATE406155T1 - Triptolid-prodrugs zur krebstherapie - Google Patents

Triptolid-prodrugs zur krebstherapie

Info

Publication number
ATE406155T1
ATE406155T1 AT02704187T AT02704187T ATE406155T1 AT E406155 T1 ATE406155 T1 AT E406155T1 AT 02704187 T AT02704187 T AT 02704187T AT 02704187 T AT02704187 T AT 02704187T AT E406155 T1 ATE406155 T1 AT E406155T1
Authority
AT
Austria
Prior art keywords
cancer therapy
triptolide prodrugs
prodrugs
triptolide
irinotecan
Prior art date
Application number
AT02704187T
Other languages
English (en)
Inventor
John Fidler
Ke Li
Original Assignee
Pharmagenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmagenesis Inc filed Critical Pharmagenesis Inc
Application granted granted Critical
Publication of ATE406155T1 publication Critical patent/ATE406155T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT02704187T 2001-01-19 2002-01-18 Triptolid-prodrugs zur krebstherapie ATE406155T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/766,156 US6620843B2 (en) 2001-01-19 2001-01-19 Anticancer treatment using triptolide prodrugs

Publications (1)

Publication Number Publication Date
ATE406155T1 true ATE406155T1 (de) 2008-09-15

Family

ID=25075572

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02704187T ATE406155T1 (de) 2001-01-19 2002-01-18 Triptolid-prodrugs zur krebstherapie

Country Status (8)

Country Link
US (1) US6620843B2 (de)
EP (1) EP1359909B1 (de)
JP (1) JP2004517882A (de)
AT (1) ATE406155T1 (de)
AU (1) AU2002237884B2 (de)
CA (1) CA2435322A1 (de)
DE (1) DE60228544D1 (de)
WO (1) WO2002056835A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4680589B2 (ja) * 2002-05-31 2011-05-11 ファーマジェネシス, インコーポレイテッド アポトーシスおよび免疫抑制の調節のためのトリプトリド誘導体
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
JP2006513209A (ja) * 2002-12-17 2006-04-20 ファーマジェネシス, インコーポレイテッド 免疫調節因子および抗癌剤としてのトリプトライド誘導体
US6943259B2 (en) * 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
US7820834B2 (en) * 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
EP1722806A4 (de) * 2004-02-09 2009-09-16 Pharmagenesis Inc Verfahren zur isolierung von triptolid-verbindungen aus tripterygium wilfordii
ES2385716T3 (es) * 2004-03-02 2012-07-30 Pharmagenesis, Inc. Derivados en el anillo de lactona de triptolida como inmunomoduladores y agentes anticáncer
WO2006012204A2 (en) * 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
US8617906B2 (en) * 2004-10-13 2013-12-31 Pharmagenesis, Inc. Identification and screening of triptolide target molecules
EP1946758A1 (de) * 2007-01-18 2008-07-23 Pierre Fabre Medicament Behandlung akuter myeloischer Leukämie
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
AU2010210594B2 (en) * 2009-02-05 2015-02-12 Pharmagenesis, Inc. Triptolide C-ring derivatives as anticancer agents and immune modulators
US9150600B2 (en) 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
MY160392A (en) * 2009-05-07 2017-03-15 Univ Minnesota Triptolide prodrugs
US20130195896A1 (en) * 2010-04-07 2013-08-01 Steward Research And Specialty Projects Corporation Compositions and methods for the treatment of a neoplasia
WO2013130603A1 (en) 2012-02-27 2013-09-06 Board Of Regents, The University Of Texas System Ganglioside gd2 as a marker and target on cancer stem cells
CA3013619A1 (en) * 2016-02-04 2017-08-10 The Johns Hopkins University Glucose conjugates of triptolide, analogs and uses thereof
CN107698653B (zh) * 2017-10-11 2019-08-27 中国农业科学院蜜蜂研究所 一种雷公藤甲素半抗原及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005108A (en) 1973-04-03 1977-01-25 Research Corporation Novel anti-leukemic diterpenoid triepoxides
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6548537B1 (en) * 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
DE69932649T2 (de) * 1998-09-02 2007-08-09 Pharmagenesis, Inc., Palo Alto Triptolid-Prodrugs mit hoher Wasserlöslichkeit
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6569893B2 (en) * 2001-03-15 2003-05-27 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents

Also Published As

Publication number Publication date
EP1359909A2 (de) 2003-11-12
WO2002056835A3 (en) 2003-02-27
AU2002237884B2 (en) 2006-08-17
EP1359909B1 (de) 2008-08-27
CA2435322A1 (en) 2002-07-25
JP2004517882A (ja) 2004-06-17
US6620843B2 (en) 2003-09-16
EP1359909A4 (de) 2005-03-09
WO2002056835A2 (en) 2002-07-25
US20020099051A1 (en) 2002-07-25
DE60228544D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
DE60228544D1 (de) Triptolid-prodrugs zur krebstherapie
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
PT1242060E (pt) Tratamento da doenca metastatica
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
DK1556058T3 (da) Farmaceutiske præparater omfattende östetrolderivater til anvendelse i cancerterapi
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
IL146125A0 (en) Novel quinones as disease therapies
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
WO2007008200A8 (en) Wortmannin analogs and methods of using same in combination with chemotherapeutic agents
DE60124387D1 (de) Synergistische kombination zur behandlung von kolorektalkarzinom
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
EP1635764A4 (de) Konjugat für spezifisches targeting von anti-krebsmitteln gegen krebszellen und seine herstellung
HUP0302913A3 (en) Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same
MX2007004596A (es) Nitrobenzoindoles y su uso en terapia del cancer.
WO2005123908A3 (en) Novel cancer cell lines and uses thereof
MXPA05008902A (es) Soluciones de drogas en mentol.
PL1803456T3 (pl) Kompozycje farmaceutyczne zawierające L-733060 do zastosowania w leczeniu guzów nowotworowych
TW200504051A (en) Novel acridine derivatives and their use as medicaments
WO2004026846A8 (en) Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
AR023726A1 (es) Terapia con gch para el tratamiento del cancer de mama
TR200302193T4 (tr) Kombinasyon kemoterapisi.
DE502004007950D1 (en) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
WO2007008490A3 (en) Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties